Development of novel therapeutic approaches based on the elucidation of disease specific metabolism in osteosarcoma
| Project/Area Number |
18K07247
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50010:Tumor biology-related
|
|---|
| Research Institution | Hoshi University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 骨肉腫 / 転移巣 / 治療抵抗性 / 代謝 |
|---|
| Outline of Final Research Achievements |
Novel therapies for refractory osteosarcoma (OS) must be developed. We focused on metabolism and performed metabolome analyses using our unique mouse model. Glycolysis and protein synthesis were upregulated in metastatic cells. Consistent with this, cytarabine exhibited a potent antitumor effect. Based on metabolite levels, non-adherent conditions were more similar to the in vivo environment than adherent conditions. A drug screen identified trametinib that preferentially decreased the viability of non-adherent cells. Notably, activation status of several kinases and crosstalk between MEK-ERK and PI3K-AKT pathways varied in OS, that might determine the response to MEK inhibition. A single dose of trametinib decreased primary tumors and CTCs. Moreover, combined administration of trametinib and anticancer drugs was effective for metastasis.
Thus, combination of trametinib and agents targeting metabolism such as cytarabine holds therapeutic potential for treatment of OS.
|
| Academic Significance and Societal Importance of the Research Achievements |
難治性悪性腫瘍である骨肉腫は、特に転移巣の治療が今なお困難である。そこで、独自に樹立した骨肉腫マウスモデルを用いて肺転移巣の細胞内代謝を解析し、その知見をもとに分子標的療法を用いた新たな治療法の選択肢を開発した。具体的には、がん細胞の生存に必要なMEK-ERK細胞シグナルの阻害と核酸合成代謝の阻害は、転移巣を含め強い抗腫瘍効果を認めることが明らかとなった。代謝解析と遺伝子発現解析、薬剤スクリーニングを組み合わせた解析は、骨肉腫など独特の性質を有する希少悪性疾患の新規治療法開発に有効である可能性が示唆された。
|
Report
(4 results)
Research Products
(14 results)
